curve imageHomeProductsContact UsSearch
CorporateAbout PallInvestor InformationPress ReleasesEventsWorldwide Locations
Main Image Public Relations Contact Information

You are about to review presentations, news releases, reports and/or filings of Pall Corporation that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Pall Corporation will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, news releases, reports and/or filings by Pall Corporation.
Printer-Friendly variant for news releases
Pall Corporation Earnings Up 26%



Back

Pall Corporation Earnings Up 26%

East Hills, NY (June 9, 2008) - - Pall Corporation (NYSE: PLL) today reported its full financial results for the third quarter ended April 30, 2008.

Sales and Earnings Overview

Third quarter sales increased 18.3% to $661.7 million compared to the third quarter of fiscal 2007. Diluted earnings per share were $0.51 compared to $0.40 (as restated). Net earnings were $63.3 million versus $50.4 million (as restated). Pro forma earnings per share excluding restructuring and other charges were $0.54 versus last year's $0.45 (as restated).

Sales for the nine months ended April 30, 2008 were approximately $1.8 billion, a 15.3% increase over the comparable period. Diluted EPS were $1.19, up from $0.89 (as restated). Net earnings were $147.4 million compared to last year's $110.7 million (as restated). Pro forma earnings excluding restructuring and other charges were $1.36 per share versus $1.02 (as restated) a year ago.

Sales in local currency (LC) increased $53.5 million, or 9.6%, in the quarter and $132.2 million, or 8.3%, for the nine months. Foreign currency translation increased reported sales by $48.8 million or 8.7%, for the quarter, and $112.6 million, or 7%, for the nine months. The impact of foreign currency translation added approximately $0.04 to earnings per share in the quarter and $0.08 for the nine months.

Eric Krasnoff, Chairman and CEO, stated, "Pall's market, application and geographic diversity give our Total Fluid Management capability teeth. Sales growth was again broad-based across markets and geographies as the Company's technologies are increasingly applied to solve a wide range of fluid management challenges.

Our well-established process improvement initiatives continue to drive costs down. Despite a 66% increase in systems sales this quarter, gross margins approached 49%. Our working capital management initiatives improved operating cash flow more than 40% within the quarter to over $90 million. We continue to make significant progress toward our short and long-term goals."

Life Sciences - Third Quarter Highlights

     
(Dollar Amounts in Thousands)
 

Sales:

APR. 30, 2008 % CHANGE % CHANGE IN LC
Medical $ 124,555 2.1 (2.9)  
BioPharmaceuticals   128,441 19.9 9.9
Total Life Sciences segment $ 252,996 10.5 3.1
 
% OF SALES
 
Gross profit $ 133,827 52.9
Operating profit $ 55,928 22.1

Within Life Sciences, sales in BioPharmaceuticals increased almost 10%. Consumables sales exceeded 6% growth and were particularly strong in Europe as vaccine production and biotech activity increased.

As expected, Medical sales decreased just under 3% on lower Blood Filtration sales. Other products within the Medical portfolio, including hospital water filters and disposable systems for cell therapy applications, posted solid results. Laboratory product sales increased over 9%.

Operating profit margin improved to 22.1% reflecting price increases and SG&A cost reductions.

Industrial - Third Quarter Highlights

     
(Dollar Amounts in Thousands)
 

Sales:

APR. 30, 2008 % CHANGE % CHANGE IN LC
General Industrial $ 252,253 30.5 19.1
Aerospace and Transportation 79,143 26.8 20.1
Microelectronics   77,288 3.5 (4.0)
Total Industrial segment $ 408,684 23.7 14.1
 
% OF SALES
Gross profit $ 189,139 46.3
Operating profit $ 66,181 16.2

Pall Industrial delivered a very strong quarter. Every market within General Industrial reported double-digit sales increases. Growth in Municipal Water and Food and Beverage was particularly robust. Systems sales, which are concentrated within General Industrial, grew close to 60%. The installed base of systems within these markets helped to drive consumable sales growth of nearly 10%. Long-term customer partnerships, which lead to a combination of strong system and consumable sales, are the goal of Pall's Total Fluid Management (SM) strategy.

Within Aerospace and Transportation, Commercial Aerospace sales grew 16% driven by strong after-market demand and increased sales to airframe manufacturers. Military sales increased about 31% aided by helicopter upgrade projects in the U.S. and military water systems in Asia.

Microelectronics sales were down 4% as the cyclical downturn in the semiconductor market continues. Our macroelectronics market continued to grow with demand for high-tech electronics and solar cells.

Operating profit increased about 22% to $66.2 million while operating profit margin declined slightly on very strong systems sales.

Conclusion/Outlook

Mr. Krasnoff concluded, Looking at this full fiscal year, we expect sales growth in the mid-single digit range with Pall Industrial slightly outpacing Pall Life Sciences. Gross margins are expected to be level to slightly improved and SG&A expense to decrease to just over 29% of sales. Pro forma earnings per share are expected to be at or above the high end of our guidance range."

Conference Call

On Tuesday June 10, 2008, at 8:30 am ET, Pall Corporation will host a conference call to review these results. The call will be webcast and individuals can access it at www.pall.com/investor. Listening to the webcast requires audio speakers and Microsoft Windows Media Player software. The webcast will be archived for 30 days.

Special Note on Financial Tables

The 2007 financial tables presented below reflect the restatement of interest expense and provision for taxes. For further details on the restatement, refer to Note 2, Audit Committee Inquiry and Restatement, to the consolidated financial statements in the Company's fiscal year 2007 Annual Report on Form 10-K.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2007 were $2.2 billion. The Company is headquartered in East Hills, New York and has extensive operations around the world. For more information visit Pall at http://www.pall.com./

Forward-Looking Statements

The matters discussed in this release contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this release and in the Companys other written and oral reports are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. All statements regarding future performance, earnings projections, earnings guidance, managements expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Such risks and uncertainties include, but are not limited to: risks relating to the Companys restatement of prior period financial statements, including the risks associated with the pending IRS audit and pending SEC and Department of Justice investigations and litigation proceedings; risks associated with the Companys planned cash management initiatives, which may result in changes in the Company's effective tax rate; changes in product mix and product pricing may affect the Companys operating results particularly as the systems business expands in which significantly longer sales cycles are experienced with less predictable revenue and profitability and less certainty of future revenue streams from related consumable product offerings and services; increases in costs of manufacturing and operating costs, including energy and raw materials; the Companys ability to achieve the savings anticipated from its cost reduction and margin improvement initiatives including the timing of completion of its facilities rationalization initiative; fluctuations in foreign currency exchange rates and interest rates; regulatory approval or market acceptance of new technologies; changes in demand for the Companys products and business relationships with key customers and suppliers including delays or cancellations in shipments; success in enforcing patents and protecting proprietary products and manufacturing techniques; risks associated with the completion or integration of acquisitions; domestic and international competition; and global and regional economic conditions, including particularly the impact of current challenging conditions in the United States that may also have global implications; and legislative, regulatory and political developments. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them. You should carefully consider these factors as well as the additional risk factors outlined in more detail in our most recent Annual Report on Form 10-K under Item 1A, Risk Factors, and in other filings the Company makes with the Securities and Exchange Commission.

Management uses certain non-GAAP measurements to assess the Company's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing the Company's financial position and results of operations. The Company has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations.

PALL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in Thousands)
   
APR. 30, 2008 JUL. 31, 2007
 
Assets:
 
Cash and cash equivalents $ 396,837 $ 443,036
Accounts receivable 590,374 551,393
Inventories 524,867 471,467
Other current assets   126,161   140,481
Total current assets   1,638,239   1,606,377
 
Property, plant and equipment, net 637,986 607,900
Other assets   627,413   494,569
Total assets $ 2,903,638 $ 2,708,846
 
Liabilities and Stockholders' Equity:
 
Short-term debt $ 49,621 $ 41,720
Accounts payable, income taxes and other current liabilities   531,019   790,470
Total current liabilities   580,640   832,190
 
Long-term debt 717,384 591,591
Deferred taxes and other non-current liabilities   459,711   224,464
Total liabilities 1,757,735 1,648,245
 
Stockholders' equity   1,145,903   1,060,601
Total liabilities and stockholders' equity $ 2,903,638 $ 2,708,846

 

PALL CORPORATION

CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
(Amounts in thousands, except per share data)
 
 
THIRD QUARTER ENDED NINE MONTHS ENDED
APR. 30, 2008 APR. 30, 2007 APR. 30, 2008 APR. 30, 2007
(As Restated) (As Restated)
Net sales $ 661,680 $ 559,347 $ 1,848,434 $ 1,603,565
Cost of sales   338,714   282,227(b)     975,876   846,303 (b)  
Gross profit   322,966   277,120   872,558   757,262
% of sales 48.8% 49.5% 47.2% 47.2%
Selling, general and administrative expenses 195,485 167,677 545,317 493,255
Research and development   18,537   15,656   53,524   45,167

Earnings before restructuring and other charges/gains), net ("ROTC"), interest
expense, net, and income taxes

108,944 93,787 273,717 218,840
ROTC 5,495 (a)   8,620 (b)   28,123 (a)   22,060 (b)  
Interest expense, net   9,944   9,171   25,728   29,626
Earnings before income taxes 93,505 75,996 219,866 167,154
Provision for income taxes   30,231   25,625   72,502 (a)      56,435
Net earnings $ 63,274 $ 50,371 $ 147,364 $ 110,719
 
Earnings per share:
Basic $ 0.51 $ 0.41 $ 1.20 $ 0.90
Diluted $ 0.51 $ 0.40 $ 1.19 $ 0.89
 
Average shares outstanding:
Basic 122,929 123,399 123,111 123,110
Diluted 124,159 124,781 124,316 124,662
 
Net earnings as reported $ 63,274 $ 50,371 $ 147,364 $ 110,719
ROTC and one-time purchase accounting adjustment, after pro forma tax effect 3,764 (a)   5,675 (b)   19,089 (a)   16,137 (b)  
Tax adjustments   -   -   2,435 (a)     -
Pro forma earnings $ 67,038 $ 56,046 $ 168,888 $ 126,856
 
Diluted earnings per share as reported $ 0.51 $ 0.40 $ 1.19 $ 0.89
ROTC and one-time purchase accounting adjustment, after pro forma tax effect 0.03 (a)   0.05 (b)   0.15 (a)   0.13 (b)  
Tax adjustments   -   -   0.02 (a)     -
Pro forma diluted earnings per share $ 0.54 $ 0.45 $ 1.36 $ 1.02
 
(a) ROTC in the quarter and the nine months includes charges of $1,059 (1 cent per share, after pro forma tax effect) and $10,021 (6 cents per share, after pro forma tax effect), respectively, primarily comprised of severance and other costs related to the Company's cost reduction programs, including its facilities rationalization initiative. ROTC in the quarter and nine months also includes $4,436 (2 cents per share, after pro forma tax effect) and $18,102 (9 cents per share, after pro forma tax effect) primarily comprised of legal and other professional fees related to the previously reported matters under inquiry by the audit committee of the Companys board of directors.
 
Provision for income taxes in the nine months includes a charge of $2,435 (2 cents per share) resulting from newly enacted tax legislation in a foreign tax jurisdiction. Pro forma earnings exclude this item as it is deemed to be non-recurring in nature.
 
(b) Cost of sales includes incremental depreciation and other adjustments of $377 in the quarter and $2,893 (2 cents per share, after pro forma tax effect) in the nine months primarily recorded in conjunction with the Companys facilities rationalization initiative.
 
ROTC in the quarter includes charges of $8,420 (5 cents per share, after pro forma tax effect) primarily comprised of severance and other costs related to the Company's cost reduction programs, including its facilities rationalization initiative. ROTC in the nine months includes a charge of $18,144 (9 cents per share, after pro forma tax effect) primarily comprised of severance costs and an impairment charge on certain long-lived assets partly offset by a gain on the sale of a facility. The charges in the nine months relate to the Company's cost reduction programs, including its facilities rationalization initiative. In addition, the quarter and nine months include charges of $200 and $3,916 (2 cents per share, after pro forma tax effect), respectively related to an increase in environmental reserves and a legal settlement.

 

PALL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(Unaudited)
(Amounts in Thousands)
   
 
NINE MONTHS ENDED
APR. 30, 2008 APR. 30, 2007
 
Net cash provided by operating activities $ 16,455   $ 213,554  
 
Investing activities:
 
Disposals of long-lived assets 5,560 44,609
Capital expenditures (76,466)   (54,086)  
Other   (6,121)     (3,648)  
Net cash used by investing activities   (77,027)     (13,125)
 
Financing activities:
 
Dividends paid (44,170) (41,521)
Notes payable and long-term borrowings 98,540 (109,802)
Purchase of treasury stock (78,211) (51,016)
Other   16,266     41,406  
Net cash used by financing activities   (7,575 )     (160,933)
 
Cash flow for period (68,147)   39,496
Cash and cash equivalents at beginning of year 443,036 317,657
Effect of exchange rate changes on cash   21,948     7,519  
Cash and cash equivalents at end of period $ 396,837   $ 364,672  
 
 

Free cash flow:

Net cash provided by operating activities $ 16,455 $ 213,554
Less capital expenditures   76,466     54,086  
Free cash flow $ (60,011)   $ 159,468  

 

PALL CORPORATION

SUMMARY OPERATING PROFIT BY SEGMENT
(Unaudited)
(Dollar Amounts in Thousands)
     
 
THIRD QUARTER ENDED NINE MONTHS ENDED
APR. 30, 2008 APR. 30, 2007 APR. 30, 2008 APR. 30, 2007
 

Life Sciences

Sales $ 252,996 $ 229,044 $ 712,090 $ 633,981
Cost of sales (a)   119,169   106,994   345,772   310,691
Gross profit 133,827 122,050 366,318 323,290
% of sales 52.9% 53.3% 51.4% 51.0%
 
Selling, general and administrative expenses 67,763 63,369 192,492 182,897
Research and development   10,136   8,560   29,962   24,048
Operating profit $ 55,928 $ 50,121 $ 143,864 $ 116,345
% of sales   22.1%   21.9%   20.2%   18.4%

Industrial

Sales $ 408,684 $ 330,303 $ 1,136,344 $ 969,584
Cost of sales (a)   219,545   174,856   630,104   532,719
Gross profit 189,139 155,447 506,240 436,865
% of sales 46.3% 47.1% 44.5% 45.1%
 
Selling, general and administrative expenses 114,557 94,105 315,977 279,838
Research and development   8,401   7,096   23,562   21,119
Operating profit $ 66,181 $ 54,246 $ 166,701 $ 135,908
% of sales   16.2%   16.4%   14.7%   14.0%
 
CONSOLIDATED:
Operating profit $ 122,109 $ 104,367 $ 310,565 $ 252,253
General corporate expenses   13,165   10,203   36,848   30,520
Earnings before ROTC, interest and income taxes 108,944 94,164 273,717 221,733
ROTC (a) 5,495 8,997 28,123 24,953
Interest expense, net (b)   9,944   9,171   25,728   29,626
Earnings before income taxes $ 93,505 $ 75,996 $ 219,866 $ 167,154
 

(a) Included in ROTC for the purpose of evaluation of segment profitability are incremental depreciation and other adjustments recorded in cost of sales of $377 and $2,893 in the quarter and nine months ended April 30, 2007, respectively, primarily recorded in conjunction with the Company's facilities rationalization initiative.

 

(b) Interest expense, net and Earnings before income taxes have been restated for the quarter and nine months ended April 30, 2007 as a result of matters that led to the previously reported audit committee inquiry.

 

PALL CORPORATION

SUPPLEMENTAL SEGMENT SALES INFORMATION BY MARKET AND GEOGRAPHY
(Unaudited)
(Dollar Amounts in Thousands)
         
EXCHANGE % CHANGE
RATE IN LOCAL
THIRD QUARTER ENDED APR. 30, 2008 APR. 30, 2007 % CHANGE IMPACT CURRENCY
 

Life Sciences

-------- Increase/(Decrease) ---------

By Market:
Medical $ 124,555 $ 121,934 2.1 $ 6,182 (2.9)
BioPharmaceuticals   128,441   107,110 19.9   10,715 9.9
Total Life Sciences